Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

被引：0
|
作者：
Nadeem, Omar [1 ]
Redd, Robert [1 ]
Mo, Clifton [1 ]
Laubach, Jacob [1 ]
Richardson, Paul G. [1 ]
Prescott, Julia [1 ]
Marto, Marjorie [1 ]
Davie, Christine [1 ]
Ricciardi, Caroline [1 ]
Murphy, Elizabeth [1 ]
Bertoni, Meredith [1 ]
Choden, Dechen [1 ]
Magidson, Sophie [1 ]
Sheehan, Brian [1 ]
Shrestha, Hira [1 ]
Sperling, Adam S. [1 ]
O'Donnell, Elizabeth K. [2 ]
Ghobrial, Irene M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-099
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [41] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [42] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
    Huang, Shang-Xiao
    Luo, Peng-Hui
    Wang, Han-Lei
    Mo, Dun-Chang
    Huang, Jian-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
  • [43] Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma
    Rahbari, Kian J.
    Nosrati, Jason D.
    Spektor, Tanya M.
    Berenson, James R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : E339 - E343
  • [44] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    de Boer, Carla
    Khokhar, Nushmia Z.
    Yeh, Howard
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2016, 128 (14) : 1821 - 1828
  • [45] Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
    Uttervall, Katarina
    Bruchfeld, Johanna Borg
    Gran, Charlotte
    Walinder, Goran
    Mansson, Robert
    Lund, Johan
    Gahrton, Gosta
    Alici, Evren
    Nahi, Hareth
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 247 - 254
  • [46] Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
    Richardson, P. G.
    Lonial, S.
    Jakubowiak, A.
    Jagannath, S.
    Raje, N.
    Avigan, D.
    Ghobrial, I. M.
    Schlossman, R.
    Mazumder, A.
    Munshi, N. C.
    Vesole, D.
    Joyce, R.
    Doss, D.
    Warren, D.
    Lunde, L.
    Lukas, R.
    Kaster, S.
    Shea, K.
    Delaney, C.
    Lauria, M.
    Mitsiades, C.
    Hideshima, T.
    Knight, R.
    Esseltine, D. L.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S38 - S38
  • [47] Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics
    Zhong, Yuping
    Chu, Xiaoxia
    Xu, Junqing
    Liu, Xiaoqian
    Yuan, Chenglu
    Zhou, Xia
    Wu, Hongying
    Wang, Yayun
    Yu, Shuyuan
    Zhang, Hongyan
    Mei, Jay
    BLOOD, 2023, 142
  • [48] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [49] Understanding high-risk smoldering multiple myeloma
    Kreiniz, Natalia
    Gertz, Morie A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1361 - 1372
  • [50] Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
    Parrondo, Ricardo D.
    Laplant, Betsy R.
    Elliott, Jamie
    Fernandez, Andre
    Flott, Caitlin J.
    Arrington, Diedre
    Chapin, Dustin
    Brown, Jade
    Das, Saurav
    Roy, Vivek
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345